Tarceva - Erlotinib - Genentech/Osi pharmaceuticals - Tyrosine kinase inhibitor approved for NSCLC

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2004年 / 39卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：568 / 568
页数：1
相关论文
共 50 条
  • [1] Antitumor activity of the EGFR/TK inhibitor Tarceva™ (erlotinib, OSI-774) in tumor models
    Desai, B
    Higgins, B
    Smith, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S63 - S64
  • [2] Long-Term Treatment of Advanced Hepatocellular Carcinoma with the Tyrosine Kinase Inhibitor Erlotinib (Tarceva®) - A Case Report
    Hass, H. G.
    Denzlinger, C.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (01): : 27 - 29
  • [3] While AstraZeneca shares tumble 12% after the Iressa study data press release, OSI Pharmaceuticals and Genentech update on Tarceva
    不详
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1514 - 1514
  • [4] Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel
    Mita, A
    Forouzesh, B
    Hidalgo, M
    Takimoto, C
    Norris, J
    Nadler, P
    Wood, D
    Zitelli, A
    Slack, J
    Rowinsky, E
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S53
  • [5] Clinical stabilization of a rapidly progressing bone metastasizing squamous cell carcinoma using the receptor tyrosine kinase inhibitor erlotinib (Tarceva®)
    Jalili, A.
    Pinc, A.
    Brunner, P.
    Bauer, W.
    Toth, J.
    Stingl, G.
    Wagner, S. N.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (09): : 755 - 756
  • [6] Clinical stabilization of a rapidly progressing bone metastasizing squamous cell carcinoma using the receptor tyrosine kinase inhibitor erlotinib (Tarceva®)
    Jalili, A.
    Pinc, A.
    Brunner, P. M.
    Bauer, W.
    Toth, J.
    Stingl, G.
    Wagner, S. N.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (02) : 195 - 195
  • [7] Axitinib: A Photoswitchable Approved Tyrosine Kinase Inhibitor
    Schmidt, Dorian
    Rodat, Theo
    Heintze, Linda
    Weber, Jantje
    Horbert, Rebecca
    Girreser, Ulrich
    Raeker, Tim
    Bussmann, Lara
    Kriegs, Malte
    Hartke, Bernd
    Peifer, Christian
    CHEMMEDCHEM, 2018, 13 (22) : 2415 - 2426
  • [8] Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
    Lepper, ER
    Swain, SM
    Tan, AR
    Figg, WD
    Sparreboom, A
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 796 (01): : 181 - 188
  • [9] Assessment of early response to tyrosine kinase inhibitor (erlotinib) in stage IIIB/IV NSCLC by PET/CT
    Benz, Matthias
    Walter, Franziska
    Garon, Edward
    Phelps, Michael
    Czernin, Johannes
    Allen-Auerbach, Martin
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [10] A c-Met receptor tyrosine kinase inhibitor offers increased radiosensitization in NSCLC after pretreatment with Erlotinib
    Welsh, James
    Ellsworth, Ron
    Mahadevan, Daruka
    Bearss, David
    Komaki, Ritsuko
    Stea, Baldassarre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S957 - S958
12345